Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833481 | 0.81 | NPC1 (0.54) | EPHX1NPC1MAPTRAB9AROCK2 | |
| SCHEMBL4994830 | 0.80 | HRH3 (0.56) | EPHX1NPC1MAPTRAB9AROCK2 | |
| SCHEMBL3840654 | 0.77 | MAPT (0.64) | EPHX1NPC1MAPTRAB9AROCK2 | |
| SCHEMBL1082254 | 0.76 | NPC1 (0.49) | EPHX1NPC1MAPTRAB9AROCK2 | |
| SCHEMBL312970 | 0.75 | KDM4E (0.60) | MAPTROCK2CYP3A4CHRNA7MAOA | |
| SCHEMBL312418 | 0.75 | ALDH1A1 (0.60) | EPHX1NPC1MAPTRAB9AROCK2 | |
| SCHEMBL13003354 | 0.73 | POLB (0.64) | NPC1MAPTRAB9AROCK2CYP3A4 | |
| SCHEMBL312715 | 0.71 | ALDH1A1 (0.53) | EPHX1NPC1MAPTRAB9ACHRNA7 | |
| SCHEMBL15039528 | 0.70 | ROCK2 (0.63) | ROCK2 | |
| SCHEMBL12893941 | 0.69 | LTA4H (0.49) | NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093285-B2 | Aminopiperidinyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090247568-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247568-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | MAOB, ADORA2B, HTR1B | EPHX1 1984/4885NPC1 2989/4885MAPT 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.